OncLive TV

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the combination of temozolomide (Temodal) and depatuxizumab mafodotin (depatux-m) in the treatment of patients with glioblastoma.

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the potential of biosimilars in oncology.

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the evolution of immunotherapy in metastatic bladder cancer.

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of pembrolizumab in melanoma.

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the significance of the CheckMate-041 trial for patients with head and neck cancer.

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses sequencing therapies in prostate cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the use of immunotherapy in genitourinary cancer.

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses challenges with immunotherapy in patients with Merkel cell carcinoma

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses bacillus Calmette-Guérin (BCG) progression in non-muscle invasive bladder cancer (NMIBC).

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the use of biosimilars in the United Kingdom for the treatment of cancer.

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the combination of PARP inhibitors and immunotherapy.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the evolution of antibodies for the treatment of lymphoma.

John Primrose, MD, ChB, FRCS, professor of medicine/surgery, University of Southampton, United Kingdom, discusses the impact of adjuvant capecitabine in patients with biliary tract cancer.

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses combination therapies in non–small cell lung cancer (NSCLC).

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses novel therapies for patients with metastatic breast cancer.

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses treatment for patients with uterine leiomyosarcoma.

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the use of checkpoint inhibitors in multiple myeloma.

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses next-generation sequencing in gastrointestinal malignancies.

Missak Haigentz, MD, chief of Hematology and Oncology at Morristown Medical Center, medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at the Carol G. Simon Cancer Center, discusses the impact that immunotherapy has had on the treatment of patients with head and neck cancer.

Gonzalo Sapisochin, MD, assistant professor of surgery, University of Toronto, discusses neoadjuvant treatment for patients with hepatocellular carcinoma.

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses central nervous system involvement in HER2-positive breast cancer.

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the treatment of patients with p53-mutated mantle cell lymphoma.

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the treatment of patients with early-stage non–small cell lung cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses studies that demonstrate the value of PARP inhibitors in the treatment of patients with ovarian cancer.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses remaining questions with immunotherapy in bladder cancer.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses adjuvant studies with biosimilars in oncology.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

Rebecca Dent, MD, senior consultant, National Cancer Center, Singapore, discusses ipatasertib in the treatment of patients with triple-negative breast cancer.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the treatment of patients with mantle cell lymphoma.